Vaccine compositions and adjuvant

a technology of compositions and adjuvants, applied in the field of vaccine compositions, can solve the problems of concomitant infertility in both sexes, atrophy of the gonads, and interference with the ability to release, and achieve the effect of enhancing the immune response of an animal to a target immunogen

Inactive Publication Date: 2006-01-19
MILLER LOWELL +1
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] We have now invented improved methods and compositions for vaccinating animals. In accordance with this invention, the immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combina

Problems solved by technology

Antibodies to GnRH produce infertility by binding to circulating endogenous GnRH, precluding the GnRH from binding to its pituitary receptor and thereby interfering with its ability to release FSH and LH.
The severe reduction or absence of these hormones leads to atrophy of the gonads and concomitant infertility in both sexes as described above.
Despite these advantages, active immunization against GnRH has not been widely practiced due to deficiencies associated with the GnR

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine compositions and adjuvant
  • Vaccine compositions and adjuvant
  • Vaccine compositions and adjuvant

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Adjuvant

[0047] Killed cells of Mycobacterium avium subsp. avium were obtained from the commercial Johne's disease vaccine, a Mycobacterium avium bacterin (provided by Solvay Animal Health Products Inc., Mendota Heights, Minn. 55120, Product No. 09149). Each vial contains a total of 25.5 mg killed cells of Mydobacterium avium (dry weight) in 0.5 ml of mineral oil. Vials are stored at refrigerator temperature, 36° to 45° F.

[0048] A mineral oil diluent is used for preparation of the adjuvant. In a sterile 50 ml centrifuge tube, combine mineral oil (light white oil) and mannide monooleate (9:1 by weight) and vortex to mix. Store at room temperature in the sterile 50 ml vial.

[0049] A concentrated stock solution of the killed cells in mineral oil may be prepared for storage and subsequent preparation of adjuvant doses in vaccine formulations. The Stock Solution is a 1 / 30 dilution of the original Mycobacterium avium bacterin. Prepare in a sterile 50 ml centrifuge tube. Ad...

example 2

GnRH-KLH Vaccine Preparation

Preparation of MSB Buffer:

[0052] Add 7 tablets of Sigma Phosphate Buffered Saline (PBS) tablets to 200 ml distilled H2O, to give a 0.07 M Phosphate buffer at pH 7.4 with 0.96 M NaCl. Add 5.6 gm Sucrose (41 mM Sucrose) to the PBS solution. For long term stability the buffer is frozen. MSB is stable for about 30 days in refrigerator.

Preparation of GnRH / KLH conjugate:

[0053] KLH carrier protein is first subjected to maleimide activation for addition of sulfide binging groups thereto. 10 mg of the mollusk protein KLH is dissolved in the MSB buffer, and 2 mg of sulfo-SMCC is added (Pierce Chemical Co.) with gentle mixing to dissolve. The mixture is allowed to react for 1 hour at room temperature with periodic mixing. After completion of the reaction, the maleimide-activated protein is immediately purified by applying the reaction mixture to a desalting column (i.e., Sephadex G-25). The maleimide activated protein comes off on the void volume (first peak, ...

example 3

Immunocontraception of Deer

[0057] The GnRH immunocontraceptive vaccine of Example 2 was used for the immunocontraception of deer as either a two shot or single shot vaccine.

Two Shot Trial:

[0058] Deer were injected with a first, prime boost, followed by injection 1 year later with a second, boost injection of the GnRH / adjuvant vaccines of Example 1. The deer were injected with 1 ml of the vaccine composition. Titers of anti-GnRH antibodies and blood progesterone levels were monitored over a two year period immediately prior to and following treatment. The amount of the conjugate in each dose of the vaccine was 450 μg.

[0059] The results are shown in FIG. 1. Deer injected with a prime and boost vaccination of KLH-GnRH / Adjuvant in the breeding season of the first year of the trial have remained infertile through four consecutive breeding seasons (four years) without a second or third season boost vaccine. Anti-GnRH antibody titers remained at 128,000 into the third year, and droppe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to view more

Abstract

The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal against any target immunogen, and is particularly preferred for use with immunocontraceptive vaccines such as GnRH and PZP immunocontraceptive vaccines.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The invention relates to novel vaccine compositions, including immunocontraceptive vaccines, and particularly to novel adjuvants for use therein. [0003] 2. Description of the Prior Art [0004] Gonadotropin releasing hormone (“GnRH”, also known as Luteinizing Hormone Releasing Hormone, or “LHRH”), has long been recognized as being of central importance to the regulation of fertility in animals. GnRH is a decapeptide which has the same amino acid sequence, i.e., pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH2 (SEQ. ID NO. 1) in all mamals. Closely relate GnRH compounds have also been identified in other non-mammals, including fowl, and receptors for GnRH have been identified in reptiles and amphibians. In males and females, GnRH is released from the hypothalamus into the bloodstream and travels via the blood to the pituitary, where it induces the release of the gonadotropins, luteinizing hormone (LH) and follicle stimulati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61K39/04A61K39/39
CPCA61K39/0006A61K2039/55505A61K39/39A61K39/04A61P37/00
Inventor MILLER, LOWELLRHYAN, JACK
Owner MILLER LOWELL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap